Previous 10 | Next 10 |
WARREN, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that John Maxwell...
WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today receipt of the fi...
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,...
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept Therapeutics...
Gainers: [[SONO]] +22.6%. [[LB]] +14.3%. [[LOW]] +8.9%. [[FCEL]] +8.6%. [[AQST]] +6.9%.Losers: [[EVGN]] -14.9%. [[PNNT]] -7.3%. [[ZTO]] -5.8%. [[CD]] -5.5%. [[GPRO]] -5.1%. For further details see: SONO, CD, ZTO and LB among after-hours movers
Aquestive Therapeutics (AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for resubmission for approval of the company's Libervant (diazepam) Buccal Film drug candidate for management of seizure clusters.Based on the FD...
FDA confirms issues identified in FDA Complete Response Letter (CRL) of September 25, 2020 may be addressed by utilizing modeling and simulations for an updated dosing regimen FDA recommends and Aquestive agrees to a follow-up FDA meeting prior to resubmission WARREN, N.J., No...
Gainers: [[VIST]] +13.1%. [[ZM]] +10.8%. [[YALA]] +8.1%. [[MTOR]] +5.9%. [[WRE]] +5.1%.Losers: [[OLED]] -29.9%. [[PTEN]] -10.1%. [[LASR]] -5.0%. [[AQST]] -4.1%. [[GNLN]] -3.5%. For further details see: VIST, ZM, OLED and LASR among after-hours movers
Aquestive Therapeutics, Inc. (AQST) Q3 2020 Results Earnings Conference Call November 05, 2020, 08:00 AM ET Company Participants Stephanie Carrington - IR, Westwicke Keith Kendall - President and Chief Executive Officer John Maxwell - SVP and Chief Financial Officer Dan Barber - SVP and Chief...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Clearwater Paper Corporation (CLW) is expected to report for Q2 2024 Amgen Inc. (AMGN) is expected to report $4.93 for Q2 2024 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.47 for Q2 2024 Axon Enterprise Inc. (AXON) is expected to report $0.55 for Q2 2024 Ame...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...